Federation Des Caisses Desjardins Du Quebec Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Aug 30, 2024	SELL	$99.73 - $148.48 $19,946 - $29,695	-200 Closed	0 $0
Q2 2021 Aug 30, 2024	BUY	$65.78 - $105.02 $13,156 - $21,004	200 New	200 $19.4 Million
Q1 2021 Aug 30, 2024	SELL	$64.07 - $91.75 $57,662 - $82,575	-900 Reduced 75.0%	300 $20.5 Million
Q4 2020 Aug 30, 2024	SELL	$65.07 - $98.24 $6,506 - $9,824	-100 Reduced 7.69%	1,200 $103 Million
Q3 2020 Aug 30, 2024	SELL	$59.04 - $77.95 $81,770 - $107,960	-1,385 Reduced 51.58%	1,300 $84.5 Million
Q2 2020 Aug 30, 2024	SELL	$29.01 - $74.23 $50,042 - $128,046	-1,725 Reduced 39.12%	2,685 $196 Million
Q1 2020 Aug 30, 2024	BUY	$27.51 - $57.29 $121,319 - $252,648	4,410 New	4,410 $150 Million

Others Institutions Holding BHVN

# of Institutions

Shares Held

792K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account